Novartis
Jimenez to take over as Novartis chief
January 28, 2010Sales and Marketing Jimenez, Novartis, Vasella
Novartis’ long-standing chief executive and chairman, Daniel Vasella is to step down from his dual position to focus upon his …
Triple approval for Novartis in Japan
January 20, 2010Sales and Marketing Afinitor, Asia, Exforge, Galvus, Japan, Novartis, hypertension
Japanese regulators have approved three new Novartis medicines for use patients with type II diabetes, high blood pressure and advanced …
Digital Pharma: Byte-sized roundup
January 15, 2010Medical Communications Diagnostics, Novartis, Roche, digital pharma, malaria
In this week’s roundup: Roche answers cancer testing questions, Novartis uses SMS in fight against malaria, UCB goes to Facebook …
Novartis launches Ilaris in the UK
January 12, 2010Sales and Marketing Ilaris, Novartis, cryopyrin-associated periodic syndrome
Novartis has launched its new biologic Ilaris in the UK as a treatment for cryopyrin-associated periodic syndrome. The rare debilitating …
Alcon directors protest Novartis takeover bid
January 6, 2010Research and Development, Sales and Marketing Alcon, Novartis
An independent committee of directors of Alcon has expressed its disappointment with the recent takeover bid from Novartis, saying the …
Novartis to acquire majority stake in Alcon
January 5, 2010Sales and Marketing Alcon, Novartis, eye care
Novartis plans to gain a majority hold of global eye care leader Alcon, significantly boosting its presence in the sector. …
Pharma mergers and acquisitions in 2009
December 22, 2009Research and Development, Sales and Marketing Abbott, GSK, J&J, JJ, M&A, MA, Novartis, Pfizer, Wyeth, generics, industry, merger, year in review
This year saw two ‘mega mergers’ in the sector, the acquisition of Wyeth by Pfizer and the reverse takeover of …
Novartis’ COPD contender cleared in EU
December 4, 2009Sales and Marketing COPD, Novartis, resp
Novartis has been given a green light in the European Union to sell its Onbrez respiratory drug, allowing the firm …
Incyte’s Novartis cancer drug deal could be worth $1bn
December 1, 2009Research and Development Incyte, Novartis
Novartis has paid Incyte Corporation $150 million up front for the rights to two oral investigational hematology-oncology therapies.The first is …
Novartis opens $1bn flu vaccine plant
November 25, 2009Manufacturing and Production Novartis, US, vaccines
Novartis has opened a new $1 billion vaccine manufacturing plant that is the first to be set up as a …
Novartis gets German OK for swine flu vaccine
November 5, 2009Research and Development, Sales and Marketing Novartis, h1n1
Novartis’ swine flu vaccine Celtura has been approved in Germany, its first market, in what is a major milestone for …
European approval for 3-in-1 version of Exforge
October 23, 2009Sales and Marketing Diovan, Exforge, Novartis, cv, hypertension
European regulators have approved an expanded version of Novartis’ high blood pressure treatment Exforge.Exforge was first approved in Europe in …
New 2-in-1 Valturna outperforms Diovan
October 1, 2009Sales and Marketing Diovan, Novartis, Tekturna, cv, hyp, hypertension
Novartis has gained US approval for a combination of its blockbuster blood pressure drug Diovan and its follow-up product Tekturna/Rasilez.Valturna …
Europe approves two swine-flu vaccines
September 30, 2009Sales and Marketing EU, GSK, Novartis, h1n1
The European Commission has approved the use of two vaccines for the pandemic H1N1 virus, commonly known as swine flu. …
Daniel Vasella, chief executive and chairman Novartis
September 17, 2009Sales and Marketing Novartis, Vasella
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
